drugset / Trial / NCT06716658
JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Phase 2
Recruiting
48 enrolled
Institute of Hematology & Blood Diseases Hospital, China
Henan Cancer Hospital · collabSecond Xiangya Hospital of Central South University · collabThe First Affiliated Hospital of Air Force Medicial University · collabThe First Affiliated Hospital of Nanchang University · collabThe First Hospital of Jilin University · collabTianjin First Central Hospital · collabTongji Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
Indolent T/NK-cell lymphomas are a heterogeneous group of lymphoproliferative diseases originating from T/NK cells, characterized by slow growth and proliferation, but currently remain incurable. For indolent T/NK-cell lymphomas that are unresponsive to first-line treatment, there are few treatment options available and the prognosis is poor. This study is an open-label, prospective clinical trial aimed at evaluating the feasibility, efficacy, and safety of PI3K inhibitors in the treatment of relapsed/refractory indolent T/NK-cell lymphomas. Patients will be treated with Golidocitnib, with an expected overall response rate of 60% for JAK1 inhibitor Golidocitnib treatment.
Timeline
- Start
- 2024-12-25
- Primary completion
- 2026-11-15
- Completion
- 2028-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Golidocitnib | Unknown | 150 mg | Oral |